1-11999028-G-A

Variant summary

Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM1PM2PM5PP2

The NM_014874.4(MFN2):​c.749G>A​(p.Arg250Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000354 in 1,614,068 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R250W) has been classified as Pathogenic.

Frequency

Genomes: 𝑓 0.00021 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00037 ( 1 hom. )

Consequence

MFN2
NM_014874.4 missense

Scores

3
11
5

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:8B:1

Conservation

PhyloP100: 6.55
Variant links:
Genes affected
MFN2 (HGNC:16877): (mitofusin 2) This gene encodes a mitochondrial membrane protein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. This protein is involved in the regulation of vascular smooth muscle cell proliferation, and it may play a role in the pathophysiology of obesity. Mutations in this gene cause Charcot-Marie-Tooth disease type 2A2, and hereditary motor and sensory neuropathy VI, which are both disorders of the peripheral nervous system. Defects in this gene have also been associated with early-onset stroke. Two transcript variants encoding the same protein have been identified. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_pathogenic. Variant got 7 ACMG points.

PM1
In a strand (size 2) in uniprot entity MFN2_HUMAN there are 7 pathogenic changes around while only 0 benign (100%) in NM_014874.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr1-11999027-C-T is described in Lovd as [Pathogenic].
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), MFN2. . Gene score misZ 1.6575 (greater than the threshold 3.09). Trascript score misZ 3.2174 (greater than threshold 3.09). GenCC has associacion of gene with Charcot-Marie-Tooth disease type 2A2, axonal hereditary motor and sensory neuropathy, hereditary motor and sensory neuropathy type 6, Charcot-Marie-Tooth disease, axonal, autosomal recessive, type 2a2b;, multiple symmetric lipomatosis, severe early-onset axonal neuropathy due to MFN2 deficiency.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
MFN2NM_014874.4 linkuse as main transcriptc.749G>A p.Arg250Gln missense_variant 8/19 ENST00000235329.10 NP_055689.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
MFN2ENST00000235329.10 linkuse as main transcriptc.749G>A p.Arg250Gln missense_variant 8/191 NM_014874.4 ENSP00000235329 P1O95140-1

Frequencies

GnomAD3 genomes
AF:
0.000210
AC:
32
AN:
152066
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000328
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00316
Gnomad NFE
AF:
0.000323
Gnomad OTH
AF:
0.000959
GnomAD3 exomes
AF:
0.000227
AC:
57
AN:
251494
Hom.:
0
AF XY:
0.000213
AC XY:
29
AN XY:
135920
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000261
Gnomad FIN exome
AF:
0.0000462
Gnomad NFE exome
AF:
0.000404
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.000369
AC:
539
AN:
1461884
Hom.:
1
Cov.:
32
AF XY:
0.000369
AC XY:
268
AN XY:
727244
show subpopulations
Gnomad4 AFR exome
AF:
0.0000597
Gnomad4 AMR exome
AF:
0.0000447
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000252
Gnomad4 SAS exome
AF:
0.000325
Gnomad4 FIN exome
AF:
0.0000187
Gnomad4 NFE exome
AF:
0.000439
Gnomad4 OTH exome
AF:
0.000265
GnomAD4 genome
AF:
0.000210
AC:
32
AN:
152184
Hom.:
0
Cov.:
32
AF XY:
0.000242
AC XY:
18
AN XY:
74380
show subpopulations
Gnomad4 AFR
AF:
0.0000482
Gnomad4 AMR
AF:
0.000327
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000324
Gnomad4 OTH
AF:
0.000949
Alfa
AF:
0.000346
Hom.:
0
Bravo
AF:
0.000314
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000465
AC:
4
ExAC
AF:
0.000288
AC:
35
EpiCase
AF:
0.000545
EpiControl
AF:
0.000237

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:8Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:4
Uncertain significance, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineDec 04, 2023The p.Arg250Gln variant in MFN2 has been reported in the heterozygous state in 7 individuals with clinical features of Charcot-Marie-Tooth (CMT) disease (Verhoeven 2006 PMID: 16714318, McCorquodale 2011 PMID: 21258814, Sitarz 2012 PMID: 22492563, Antoniadi 2015 PMID: 26392352, Tomaselli 2016 PMID: 26930221, Rudnik-Schoneborn 2016 PMID: 25850958, Volodarsky 2021 PMID: 32376792). This variant was also reported in the compound heterozygous state with another MFN2 variant in 2 siblings with features of CMT disease with earlier disease onset. The variant was determined to be paternally inherited, and the father had not symptoms of neuropathy (Lupo 2016 PMID: 26752306). This variant has also been reported by other clinical laboratories in ClinVar (Variation ID 214653) and has been identified in 0.03% (5/15252) of Latino chromosomes by gnomAD (http://gnomad.broadinstitute.org, v.3.1.2). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, while there is some suspicion for a pathogenic role, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: PS4, PM2_Supporting. -
Uncertain significance, no assertion criteria providedclinical testingClinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center-- -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxJul 04, 2024Reported previously in unrelated individuals with Charcot-Marie-Tooth neuropathy type 2A (CMT2A) who were heterozygous for p.(R250Q), although familial segregation was not evaluated for either individual (PMID: 16714318, 21258814, 25850958); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 22492563, 30442897, 21258814, 26968897, 25850958, 31827005, 26752306, 32376792, 35399520, 24863639, 23800155, 26930221, 16714318) -
Uncertain significance, no assertion criteria providedclinical testingClinical Genetics, Academic Medical Center-- -
Charcot-Marie-Tooth disease Uncertain:2
Uncertain significance, no assertion criteria providedliterature onlyInherited Neuropathy Consortium-- -
Uncertain significance, criteria provided, single submitterclinical testingMolecular Genetics Laboratory, London Health Sciences Centre-- -
Charcot-Marie-Tooth disease type 2 Pathogenic:1
Pathogenic, low penetrance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 03, 2024This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 250 of the MFN2 protein (p.Arg250Gln). This variant is present in population databases (rs140234726, gnomAD 0.04%). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease (PMID: 21258814, 22492563, 25850958, 26930221, 32376792). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant shows reduced penetrance with mild disease symptoms, later onset and some individuals may be asymptomatic (PMID: 26930221, 25850958). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 214653). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MFN2 protein function. This variant disrupts the p.Arg250 amino acid residue in MFN2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 16714318, 26306937, 28660751, 35922214). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, this variant is reported to cause disease. However, as this variant is associated with a lower penetrance than other pathogenic alleles in the MFN2 gene, it has been classified as Pathogenic (low penetrance). -
MFN2-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesSep 02, 2022The MFN2 c.749G>A variant is predicted to result in the amino acid substitution p.Arg250Gln. This variant was previously reported in the heterozygous state in individuals who presented with Charcot-Marie-Tooth type 2 or 1 disease (Verhoeven et al. 2006. PubMed ID: 16714318; McCorquodale et al. 2011. PubMed ID: 21258814; Sitarz et al. 2012. PubMed ID: 22492563; Antoniadi et al. 2015. PubMed ID: 26392352, see supplementary table 3, rs140234726). This variant was also detected in an individual with non-ataxic spastic paraplegia and peripheral neuropathy, although the variant did not segregate with disease within the family (Gregianin et al. 2013. PubMed ID: 23800155). Additionally, the c.749G>A variant was reported in the compound heterozygous state in two brothers with early-onset sensory motor neuropathy; the unaffected father harbored this variant in the heterozygous state (Tomaselli et al. 2016. PubMed ID: 26930221). The p.Arg250Gln variant was also described in an affected individual who harbored a likely pathogenic variant in LRSAM1 (Lupo et al. 2016. PubMed ID: 26752306). Taken together, the clinical significance of this variant is classified as uncertain at this time due to the absence of conclusive functional and genetic evidence. We suspect this variant may be benign for autosomal dominant disease, although we cannot rule out the possibility that this variant may be relevant to autosomal recessive inheritance of this disorder. -
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsAug 04, 2022The p.R250Q variant (also known as c.749G>A), located in coding exon 6 of the MFN2 gene, results from a G to A substitution at nucleotide position 749. The arginine at codon 250 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been reported in a compound heterozygous state in two siblings with early-onset sensory motor neuropathy (Tomaselli PJ et al. J Peripher Nerv Syst, 2016 Mar;21:52-4), as well as in a heterozygous state in multiple unrelated individuals with Charcot-Marie-Tooth disease (CMT) (Verhoeven K et al. Brain, 2006 Aug;129:2093-102; McCorquodale DS et al. J. Neurol., 2011 Jul;258:1234-9; Sitarz KS et al. Brain, 2012 Aug;135:e219, 1-3; author reply e220, 1-3; Rudnik-Schöneborn S et al. Clin Genet, 2016 Jan;89:34-43). Another alteration at the same codon, p.R250W (c.748C>T), has been described in multiple individuals with phenotypes consistent with CMT disease (Di Meglio C et al. Brain Dev, 2016 May;38:498-506; Piscosquito G et al. J Peripher Nerv Syst, 2015 Dec;20:380-6; Sun B et al. J Peripher Nerv Syst, 2017 03;22:13-18; Verhoeven K et al. Brain, 2006 Aug;129:2093-102). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is unlikely to be causative of autosomal dominant MFN2-related neuropathy; however, its contribution to the development of autosomal recessive MFN2-related neuropathy is uncertain. -
not specified Benign:1
Likely benign, criteria provided, single submitterclinical testingAthena DiagnosticsMay 25, 2021- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.070
BayesDel_addAF
Uncertain
0.086
D
BayesDel_noAF
Pathogenic
0.20
CADD
Pathogenic
29
DANN
Pathogenic
1.0
DEOGEN2
Uncertain
0.61
D;D
Eigen
Uncertain
0.48
Eigen_PC
Uncertain
0.57
FATHMM_MKL
Uncertain
0.96
D
LIST_S2
Uncertain
0.97
D;.
M_CAP
Uncertain
0.25
D
MetaRNN
Uncertain
0.50
T;T
MetaSVM
Uncertain
0.72
D
MutationAssessor
Benign
0.23
N;N
MutationTaster
Benign
1.0
D;D;D
PrimateAI
Uncertain
0.64
T
PROVEAN
Benign
-1.1
N;N
REVEL
Pathogenic
0.71
Sift
Benign
0.032
D;D
Sift4G
Uncertain
0.0080
D;D
Polyphen
0.83
P;P
Vest4
0.63
MVP
0.91
MPC
1.2
ClinPred
0.11
T
GERP RS
5.6
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.55
gMVP
0.86

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.050
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs140234726; hg19: chr1-12059085; COSMIC: COSV52421375; API